Reports Q4 revenue $181.9M, consensus $200.1M. “Once again, we had a record number of new Korlym(R) prescribers and a record number of patients receiving Korlym in the quarter. Physicians are increasingly aware of hypercortisolism’s true prevalence and the poor health outcomes for patients who go untreated. Screening is becoming more common and the number of patients receiving appropriate care continues to increase. We are confident that our Cushing’s syndrome business will grow for many years,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Strong Buy Rating for Corcept Therapeutics Amid Promising Phase III Trial Developments
- Corcept Therapeutics price target raised to $115 from $80 at H.C. Wainwright
- Corcept Therapeutics (CORT) Q4 Earnings Cheat Sheet
- Corcept Therapeutics: Leveraging Korlym Growth and CATALYST Study for Market Expansion and Long-term Growth
- Corcept Therapeutics price target raised to $130 from $78 at Canaccord